EGErhe Gao

Erhe Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erhe Gao has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RND3 Enhances Cardiac Glucose Metabolism Through Inhibiting ACAT1-Dependent PDHA1 Acetylation and Protects Against Ischemia-Reperfusion Injury

    by Zhenyu Xiong, Yueyang Li, Yan Zhang, Zhengjun Ma, Meiying Qi, Huanle Zhang, Xiaohua Zhang, Mengyuan Jiang, Jie Liu, Erhe Gao, et al.

    BACKGROUND: Metabolic disturbances are key contributors to myocardial ischemia-reperfusion (I/R) injury, yet the underlying molecular mechanisms remain largely unclear. Rho family GTPase 3 (RND3), a cytosolic small guanosine triphosphatase (GTPase) known to antagonize ROCK1 (Rho-associated coiled-coil kinase 1), has been implicated in several cardiovascular disorders. However, its mitochondrial localization and functional role in cardiac energy metabolism and I/R injury remain unknown. METHODS: A murine model of myocardial I/R injury was established through left anterior descending coronary artery ligation. Mice with cardiomyocyte-specific knockout and overexpression of Rnd3 were generated. To investigate the role of RND3 in cardiac metabolism and I/R injury, we used 13 C-nuclear magnetic resonance, 18 F-fluorodeoxyglucose positron emission tomography/computed tomography scanning, seahorse mitochondrial energy metabolism assays, and 13 C-metabolic flux tracing. Mechanistic studies were conducted using RNA sequencing, coimmunoprecipitation, mass spectrometry, and glutathione S-transferase (GST) pulldown assays. RESULTS: Cardiomyocyte-specific deletion of Rnd3 ( Rnd3 conditional knockout, Rnd3 cKO ) resulted in impaired glucose oxidation and compensatory upregulation of fatty acid oxidation, leading to pronounced cardiac dysfunction and increased mortality. Rnd3 cKO hearts exhibited reduced pyruvate/malate-driven complex I respiration and marked uncoupling between glycolysis and the tricarboxylic acid cycle. Mechanistically, RND3 was identified as a novel mitochondrial matrix-localized small GTPase that directly binds to ACAT1 (acetyl-coenzyme A [CoA] acetyltransferase), disrupting its interaction with PDHA1 (pyruvate dehydrogenase E1α subunit) and thereby promoting PDHA1 acetylation and glucose oxidation. It is important to note that RND3 expression was significantly downregulated in both human and murine hearts after I/R insult. Loss of RND3 sensitized the hearts to I/R injury, as evidenced by reduced levels of phosphocreatine and ATP. Conversely, cardiac-specific overexpression of Rnd3 conferred protection against I/R injury, an effect that was abolished upon Pdha1 knockdown. CONCLUSIONS: Our results identify RND3 as a novel mitochondria-localized regulator of glucose oxidation that safeguards the heart against I/R injury. Therapeutic reconstitution of Rnd3 may represent a promising strategy to restore metabolic homeostasis and mitigate myocardial damage in the context of I/R.


  • Open Access

    S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models

    by Dorothea Kehr, Julia Ritterhoff, Manuel Glaser, Lukas Jarosch, Rafael E. Salazar, Kristin Spaich, Karl Varadi, Jennifer Birkenstock, Michael Egger, Erhe Gao, et al.

    BACKGROUND: The EF-hand Ca 2+ sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. The ability of S100A1 to recognize and modulate the activity of targets such as SERCA2a (sarcoplasmic reticulum Ca 2+ ATPase) and RyR2 (ryanodine receptor 2) in cardiomyocytes has mostly been ascribed to its hydrophobic C-terminal α-helix (residues 75–94). We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S100A1ct) could mimic the performance-enhancing effects of S100A1 and may be suitable as a peptide therapeutic to improve the function of diseased hearts. METHODS: We applied an integrative translational research pipeline ranging from in silico computational molecular modeling and in vitro biochemical molecular assays as well as isolated rodent and human cardiomyocyte performance assessments to in vivo safety and efficacy studies in small and large animal cardiac disease models. RESULTS: We characterize S100A1ct as a cell-penetrating peptide with positive inotropic and antiarrhythmic properties in normal and failing myocardium in vitro and in vivo. This activity translates into improved contractile performance and survival in preclinical heart failure models with reduced ejection fraction after S100A1ct systemic administration. S100A1ct exerts a fast and sustained dose-dependent enhancement of cardiomyocyte Ca 2+ cycling and prevents β-adrenergic receptor–triggered Ca 2+ imbalances by targeting SERCA2a and RyR2 activity. In line with the S100A1ct-mediated enhancement of SERCA2a activity, modeling suggests an interaction of the peptide with the transmembrane segments of the sarcoplasmic Ca 2+ pump. Incorporation of a cardiomyocyte-targeting peptide tag into S100A1ct (cor-S100A1ct) further enhanced its biological and therapeutic potency in vitro and in vivo. CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.


  • Open Access

    Extracellular PKM2 Preserves Cardiomyocytes and Reduces Cardiac Fibrosis During Myocardial Infarction

    by Yang Huang, Bin Li, Zongxiang Gui, Erhe Gao, Yi Yuan, Jenny Yang, Khan Hekmatyar, Falguni Mishra, Payton Chan, Zhiren Liu

    Substantial loss of cardiomyocytes during heart attacks and onset of other cardiovascular diseases is a major cause of mortality. Preservation of cardiomyocytes during cardiac injury would be the most effective strategy to manage these diseases in clinic. However, there is no effective treatment strategy that is able to prevent cardiomyocyte loss. We demonstrate here that the systemic administration of a recombinant PKM2 mutant (G415R) preserves cardiomyocytes and reduces cardiac fibrosis during myocardial infarction. G415R preserves cardiomyocytes by protecting the cardiomyocytes from dying and by promoting cardiomyocyte proliferation. Preservation of cardiomyocytes by extracellular PKM2 (EcPKM2) reduces cardiac fibrosis because of the decreased activation of cardiac fibroblasts. Our experiments show that EcPKM2 (G415R) exerts its action by interacting with integrin avb3 on cardiomyocytes. EcPKM2(G415R) activates the integrin–FAK–PI3K signaling axis, which subsequently suppresses PTEN expression and consequently regulates cardiomyocyte apoptosis resistance and proliferation under hypoxia and oxidative stress conditions. Our studies uncover an important cardiomyocyte protection mechanism. More importantly, the activity/action of EcPKM2 (G415R) in preserving cardiomyocyte suggesting a possible therapeutic strategy and target for the treatment of heart attacks and other cardiovascular diseases.


  • Open Access

    Excretory/secretory products from Trichinella spiralis adult worms ameliorate myocardial infarction by inducing M2 macrophage polarization in a mouse model

    by Lingqin Wu, Wenhui Yin, Jutai Wen, Shuying Wang, Huihui Li, Xiaoli Wang, Weixiao Zhang, Shuyao Duan, Qiuyu Zhu, Erhe Gao, et al.

    Background: Ischemia-induced inflammatory response is the main pathological mechanism of myocardial infarction (MI)-caused heart tissue injury. It has been known that helminths and worm-derived proteins are capable of modulating host immune response to suppress excessive inflammation as a survival strategy. Excretory/secretory products from Trichinella spiralis adult worms (Ts-AES) have been shown to ameliorate inflammation-related diseases. In this study, Ts-AES were used to treat mice with MI to determine its therapeutic effect on reducing MI-induced heart inflammation and the immunological mechanism involved in the treatment. Methods: The MI model was established by the ligation of the left anterior descending coronary artery, followed by the treatment of Ts-AES by intraperitoneal injection. The therapeutic effect of Ts-AES on MI was evaluated by measuring the heart/body weight ratio, cardiac systolic and diastolic functions, histopathological change in affected heart tissue and observing the 28-day survival rate. The effect of Ts-AES on mouse macrophage polarization was determined by stimulating mouse bone marrow macrophages in vitro with Ts-AES, and the macrophage phenotype was determined by flow cytometry. The protective effect of Ts-AES-regulated macrophage polarization on hypoxic cardiomyocytes was determined by in vitro co-culturing Ts-AES-induced mouse bone marrow macrophages with hypoxic cardiomyocytes and cardiomyocyte apoptosis determined by flow cytometry. Results: We observed that treatment with Ts-AES significantly improved cardiac function and ventricular remodeling, reduced pathological damage and mortality in mice with MI, associated with decreased pro-inflammatory cytokine levels, increased regulatory cytokine expression and promoted macrophage polarization from M1 to M2 type in MI mice. Ts-AES-induced M2 macrophage polarization also reduced apoptosis of hypoxic cardiomyocytes in vitro. Conclusions: Our results demonstrate that Ts-AES ameliorates MI in mice by promoting the polarization of macrophages toward the M2 type. Ts-AES is a potential pharmaceutical agent for the treatment of MI and other inflammation-related diseases. Graphical


  • Open Access

    Characterizing the Role of Ser670 Phosphorylation in Non-canonical Mechanisms of GRK2 Inhibition in Heart Failure

    by Heidi Cho, Kimberly Ferrero, John K. Chuprun, Erhe Gao, Walter Koch

    ID 54365 Poster Board 159 Background and Significance: Heart failure (HF) is characterized by aberrant cardiac beta-adrenergic receptor (β-AR) signaling, leading to upregulation of GPCR kinase 2 (GRK2) and subsequent phosphorylation and desensitization of β-ARs. A peptide inhibitor of GRK2, comprised of the last 194 carboxyl-terminal amino acids of GRK2 (βARKct), has been shown to bind to the G protein beta-gamma subunits, preventing GRK2 binding and β-AR desensitization. Overexpression of βARKct attenuates HF and improves outcomes in animal models. Emerging evidence indicates that following oxidative stress, mitogen-activated protein kinases (MAPKs) phosphorylate the Ser670 (S670) residue of GRK2, which induces GRK2 binding to Hsp90 and localization to mitochondria, where pro-death pathways are initiated. As S670 is also found in βARKct it may prevent endogenous GRK2 accumulation in the mitochondria. We hypothesize that βARKct-mediated cardioprotection in HF is due primarily to mitochondrial GRK2 blockade by βARKct. To test this notion, our lab has generated a cardiac-specific mutant βARKct-S670A transgenic mouse harboring a Ser-to-Ala mutation at the S670 residue that prevents Hsp90 binding and allows for endogenous GRK2 to continue to translocate to the mitochondria upon ischemic injury, while retaining βARKct in the cytosol to act on β-AR signaling pathways. Methods:In vivo hemodynamic analysis was performed to assess cardiac function in βARKct and βARKct-S670A transgenic mice and respective normal littermate controls (NLCs). Additionally, intracellular cyclic AMP (cAMP) levels in AC16 cardiomyocytes transfected with βARKct or βARKCt-S670A, and βARKct-S670D plasmids were quantified in response to increasing doses of isoproterenol. Results: Early hemodynamic analysis of the βARKct-S670A mice has demonstrated increased baseline contractility in βARKct-S670A mice compared to NLC mice, indicating comparable cardioprotective effects to βARKct mice lacking the Ser-to-Ala mutation, which are mediated by canonical pathways. In vitro cAMP quantification revealed AC16s transfected with βARKct, βARKct-S670A, and βARKct-S670D plasmids increased cAMP accumulation in response to increasing doses of isoproterenol compared to control. Conclusion: Studies characterizing the mitochondrial pathways involved in HF rescue following ischemic injury are ongoing. These findings will identify new mechanistic information of GRK2 inhibition for HF, and elucidate a new method for attenuating mitochondrial dysfunction during HF. This work is supported by NIH grants R01 HL061690-22 (W.J.K.) and T32 HL091804-11 and AHA predoctoral fellowship 23PRE1019969 (H.C.).

  • Open Access

    β3AR-dependent BDNF generation limits chronic post-ischemic heart failure

    by Seungho Jun, Alessandro Cannavo, Giuseppe Rengo, Federica Marzano, Jacopo Agrimi, Gizem Keceli, Andrea Elia, Daniela Liccardo, Giovanna G. Altobelli, Erhe Gao, et al.

    ID 24433 Poster Board 157 Rationale: Lack of brain-derived neurotrophic factor (BDNF) and/or inadequate expression/activity of its associated tropomyosin kinase receptor B (TrkB) account for brain and cardiac disorder. While β-adrenergic receptor (βAR) is responsible for the local expression of BDNF in neurons, whether a similar interaction is observed and pathophysiologically relevant in the cardiovascular system is unknown, especially in the post-ischemic myocardium with adrenergic desensitization. Moreover, it is unclear whether and how TrkB agonists counter chronic post-ischemic left ventricle (LV) decompensation. Methods: We conducted in vitro studies with neonatal rat (NRVM)/adult murine cardiomyocytes (CMs), SH-SY5Y neuronal cells, and umbilical vein endothelial cells. We assessed the degree of impact from ischemia-related injury via either in vivo coronary ligation (myocardial infarction, MI) or ex vivo isolated hearts with global ischemia-reperfusion injury (I/R) in WT, cardiomyocyte-selective BDNF KO (myoBDNF KO) or β3AR KO mice. Results: In WT hearts, early after MI (In vitro, the TrkB agonist, LM22A-4 promoted neurite outgrowth and neovascularization. Moreover, LM22A-4 and another agonist, TrkB, 7,8-dihydroflavone enhanced myocyte contractility. When given to in vivo MI mice, LM22A-4 rescued, at least in part, LV dysfunction, denervation, and hypovascularity. Of note, when given to isolated myoBDNF KO hearts, it no longer benefited post-I/R LV structure and function. Superfusing isolated murine myocyte with the β3AR-agonist, BRL-37344 enriched these cells with BDNF. Moreover, BRL-37344 limited post-I/R injury in WT mice but not in myoBDNF KO ones. Finally, the β1AR blocker that upregulates β3AR, augmented BDNF levels in the ischemic myocardium, improving in vivo post-MI dysfunction. Conclusions: Lack of BDNF accounts, at least in part, for chronic post-ischemic LV decompensation. By extension, by restoring intracardiac BDNF levels, TrkB agonists can limit the extent of ischemic injury, both in vivo and ex-in vivo. Direct and indirect cardiac β3AR stimulation via BRL-37344 or β-blocker, metoprolol, respectively, show another BDNF-centered means to arrest chronic post-ischemic HF. These findings may have relevant pharmacological implications for the treatment of chronic post-ischemic LV decompensation.

  • Open Access

    Electroacupuncture Pretreatment Mitigates Myocardial Ischemia/Reperfusion Injury via XBP1/GRP78/Akt Pathway

    by Nisha Wang, Jipeng Ma, Yan Ma, Linhe Lu, Chao Ma, Pei Qin, Erhe Gao, Mingzhang Zuo, Jian Yang, Lifang Yang

    Myocardial ischemia/reperfusion injury is a common clinical problem and can result in severe cardiac dysfunction. Previous studies have demonstrated the protection of electroacupuncture against myocardial ischemia/reperfusion injury. However, the role of X-box binding protein I (XBP1) signaling pathway in the protection of electroacupuncture was still elusive. Thus, we designed this study and demonstrated that electroacupuncture significantly improved cardiac function during myocardial ischemia/reperfusion injury and reduced cardiac infarct size. Electroacupuncture treatment further inhibited cardiac injury manifested by the decrease of the activities of serum lactate dehydrogenase and creatine kinase-MB. The results also revealed that electroacupuncture elevated the expressions of XBP1, glucose-regulated protein 78 (GRP78), Akt, and Bcl-2 and decreased the Bax and cleaved Caspase 3 expressions. By using the inhibitor of XBP1 in vitro, the results revealed that suppression of XBP1 expression could markedly increase the activities of lactate dehydrogenase and creatine kinase-MB and cell apoptosis, thus exacerbating stimulated ischemia/reperfusion-induced H9c2 cell injury. Compared with stimulated ischemia/reperfusion group, inhibition of XBP1 inhibited the downstream GRP78 and Akt expressions during stimulated ischemia/reperfusion injury. Collectively, our data demonstrated that electroacupuncture treatment activated XBP1/GRP78/Akt signaling to protect hearts from myocardial ischemia/reperfusion injury. These findings revealed the underlying mechanisms of electroacupuncture protection against myocardial ischemia/reperfusion injury and may provide novel therapeutic targets for the clinical treatment of myocardial ischemia/reperfusion injury.


  • Open Access

    Enhanced insulin‐responsive AS160 elicits cardioprotection during metabolic stress

    by Sarah Schumacher, Kamila Bledzka, Iyad Manaserh, Jessica Grondolsky, Rajika Roy, Erhe Gao, Walter Koch

    Heart disease is the leading cause of death in the United States, and cardiovascular mortality rates positively correlate with the presence of diabetes and metabolic syndrome. There is a consensus that abdominal obesity is a major driver in the pathogenesis of metabolic syndrome, with severe adverse effects on cardiovascular risk factors. In the midst of a growing recognition of the effect of adipose tissue dysfunction and adipokine imbalance on cardiovascular disease, a less‐well understood mechanism is the effect of cardiac metabolism and function on systemic metabolic homeostasis. There is increasing recognition that signals produced by the heart can affect distant organ function; however, little is known regarding mechanistic links. While elevated GRK2 activity and expression occur early in cardiovascular disease and contribute to progression, ongoing studies show cardiac restricted expression of a short, amino terminal fragment of GRK2 (βARKnt) preserves cardiac structure and function during chronic pressure overload. Surprisingly, these studies revealed a significant decrease in gonadal fat weight, equivalent to human abdominal fat, in male βARKnt mice at baseline and following cardiac stress. In contrast, cardiac overexpression of GRK2 produces an overall lean phenotype, while the peptide inhibitor of GRK2 (βARKct) enhances the obesogenic phenotype. Proteomic analysis to identify βARKnt binding partners that may underlie the improved cardiovascular and metabolic phenotype uncovered a selective functional interaction of both endogenous GRK2 and βARKnt with AKT substrate of 160kDa (AS160). AS160 has emerged as a key downstream regulator of insulin signaling, integrating physiological and metabolic cues to couple energy demand to membrane recruitment of Glut4. Our preliminary data indicate that in βARKnt mice, cardiomyocyte insulin sensitivity is improved during stress, without metabolic switching. These mice demonstrate an ~23% increase in phosphorylated Akt, ~75% increase in phosphorylated and total AS160, and upregulation of the mTORC1 pathway. Seahorse of dissociated adult cardiomyocytes and Oroboros of fresh, permeabilized cardiac tissue exhibited enhanced spare respiratory activity and ATP production in the presence of glucose and palmitate. Unlike control mice that develop insulin resistance in response to high fat diet stress, the βARKnt mice demonstrate enhanced glucose tolerance and improved insulin sensitivity (glucose tolerance test area under curve (AUC) is 2958 vs 2354; insulin tolerance AUC is 1245 vs 991.7 at 14 weeks), increased energy expenditure, and enhanced cardiac function at 4 and 14 weeks. These data suggest that the enhanced AS160‐mediated signaling in the βARKnt mice may ameliorate pathological cardiac remodeling through direct modulation of insulin signaling within cardiomyocytes, and translate these to beneficial effects on systemic metabolism. Ongoing studies seek to elucidate the underlying mechanisms of these beneficial effects, to gain insights into development of new therapeutic strategies for metabolic syndrome and obesity‐related cardiovascular disease.

  • Open Access

    GRK5 is a regulator of fibroblast activation and cardiac fibrosis

    by Akito Eguchi, Ryan Coleman, Kenneth Gresham, Erhe Gao, Jessica Ibetti, J. Kurt Chuprun, Walter J. Koch

    Pathological remodeling of the heart is a hallmark of chronic heart failure (HF) and these structural changes further perpetuate the disease. Cardiac fibroblasts are the critical cell type that is responsible for maintaining the structural integrity of the heart. Stress conditions, such as a myocardial infarction (MI), can activate quiescent fibroblasts into synthetic and contractile myofibroblasts. G protein-coupled receptor kinase 5 (GRK5) is an important mediator of cardiovascular homeostasis through dampening of GPCR signaling, and is expressed in the heart and up-regulated in human HF. Of note, GRK5 has been demonstrated to translocate to the nucleus in cardiomyocytes in a calcium-calmodulin (Ca2+-CAM)-dependent manner, promoting hypertrophic gene transcription through activation of nuclear factor of activated T cells (NFAT). Interestingly, NFAT is also involved in fibroblast activation. GRK5 is highly expressed and active in cardiac fibroblasts; however, its pathophysiological role in these crucial cardiac cells is unknown. We demonstrate using adult cardiac fibroblasts that genetic deletion of GRK5 inhibits angiotensin II (AngII)-mediated fibroblast activation. Fibroblast-specific deletion of GRK5 in mice led to decreased fibrosis and cardiac hypertrophy after chronic AngII infusion or after ischemic injury compared to nontransgenic littermate controls (NLCs). Mechanistically, we show that nuclear translocation of GRK5 is involved in fibroblast activation. These data demonstrate that GRK5 is a regulator of fibroblast activation in vitro and cardiac fibrosis in vivo. This adds to previously published data which demonstrate the potential beneficial effects of GRK5 inhibition in the context of cardiac disease. Significance Pathological remodeling of the heart is a hallmark of chronic heart failure (HF) and these structural changes further perpetuate the disease. G protein-coupled receptor (GPCR) kinase 5 (GRK5) has been shown to cause deleterious effects on the cardiomyocyte during HF; however, its effects in cardiac fibroblasts, the crucial cell type responsible for maintaining the structural integrity of the heart, is not understood. Here, we use in vitro and in vivo methods to demonstrate that inhibition of GRK5 inhibits fibroblast activation and attenuates the fibrotic response in the heart.


  • Open Access

    Activation or inhibition of PPARα-mediated fatty acid β-oxidation does not active cardiomyocyte proliferation in normal or infarcted adult mice

    by Rajika Roy, Tani Leigh, Erhe Gao, Xiaoying Zhang, Ying Tian

    Objectives: PPAR genes are known as the important regulators of fatty acid oxidation and energy homeostasis. PPARα is highly expressed in the embryonic and adult heart. Previous studies from infant mouse hearts have suggested that activation of PPARα using GW7647 treatment or cardiac-restricted activation of PPARα using αMHC-PPARα transgenic mice enhanced fatty acid β-oxidation and promoted cardiomyocyte proliferation rate in the postnatal day 4 mouse heart. Here, we further investigate the impact of PPARα-mediated fatty acid β-oxidation on cardiomyocyte proliferation in the adult mouse heart. Methods and Results: Adult wild-type (C57BL/6J) mice were subjected to five injections of GW7647, a highly specific PPARα agonist, or vehicle (saline). Cardiomyocyte proliferation was analyzed by quantification of DNA synthesis via ethynyldeoxyuridine (EdU) incorporation and quantification of cells undergoing mitosis using phosphorylated histone H3 (PH3). GW7647 treatment resulted in activation of PPARα target genes associated with fatty acid metabolism and β-oxidation, validating its biological activity. However, GW7647 treatment did not active cardiomyocyte proliferation in the normal heart. In parallel, mice were subjected to myocardial infarction (MI) using permanent coronary artery occlusion. Both GW7647-treatd wild-type mice and αMHC-PPARα transgenic mice showed no significant differences in cardiomyocyte DNA synthesis and mitosis compared with vehicle-treated wild-type mice after MI. Furthermore, inhibition of PPARα-mediated fatty acid β-oxidation using etomoxir (ETO) treatment had no impact on cardiomyocyte proliferation in both normal and infarcted hearts of wild-type mice compared with vehicle treatment. Summary: These findings suggest that activation or inhibition of PPARα-mediated fatty acid β-oxidation did not active cardiomyocyte proliferation in normal or infarcted hearts of adult mice. Any effects on cardiac function observed following PPARα activation treatment is independent of enhanced cardiomyocyte renewal in the adult heart.